SLN
Silence Therapeutics PLC
10.60$
-0.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +22.0% | +105.4% | -23.1% | -10.2% | -4.4% | +14.5% | -10.8% | -11.2% | -10.5% | -12.4% | -7.6% | |
| – | +17.7% | +122.4% | -23.1% | -10.7% | -5.0% | +13.5% | -12.5% | -10.0% | -11.2% | -13.3% | -8.3% | |
| – | +17.0% | +107.5% | -23.3% | -43.4% | +56.4% | -33.0% | -35.7% | +96.5% | -86.3% | -49.8% | +1,173.7% | |
| – | +17.0% | +180.4% | -22.4% | -13.8% | -8.8% | +16.0% | -16.4% | -10.5% | -16.7% | -17.7% | +2.8% | |
| – | +5,089.8% | -0.9% | -92.9% | -82.9% | +169.6% | +2,068.7% | +19.0% | +10.7% | +11.0% | -9.7% | -58.2% | |
| – | -1,860,500,100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | +27.4% | -2.2% | -21.5% | -1.6% | -0.5% | +30.4% | +8.5% | 0.0% | +0.1% | -2.5% | -0.3% | |
| – | +23.5% | -4.1% | -23.1% | -3.4% | -3.4% | +24.4% | +2.3% | -5.4% | -4.0% | -13.9% | -4.4% | |
| – | +25.0% | -8.7% | -14.4% | -1.7% | -26.8% | +443.8% | -76.2% | +2.3% | -4.9% | -4.9% | +3.4% | |
| – | +24.0% | -19.9% | +0.3% | -5.7% | -20.6% | +43.4% | -23.3% | +17.7% | -21.7% | -23.2% | +21.5% | |
| – | +13.4% | +1.9% | -20.8% | -24.5% | -32.8% | -35.8% | – | – | +4.7% | +4.5% | +10.8% | |
| – | -72.0% | +295.5% | +13.2% | -4.8% | -79.3% | +537.1% | -23.9% | +18.7% | -74.1% | +135.1% | +21.6% | |
| – | +10.0% | +611.3% | -28.1% | -16.0% | +13.3% | -205.3% | – | -21.3% | -15.9% | -20.7% | -22.1% | |
| – | – | – | – | – | – | – | -205.4% | – | – | – | – | |
| – | +6.2% | +11.0% | +6.3% | +0.7% | -0.9% | +1.2% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.